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Abstract
The tumor suppressor PTEN is a major brake for cell transformation, mainly due to its 
phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3] phosphatase activity that directly 
counteracts the oncogenicity of phosphoinositide 3-kinase (PI3K). PTEN mutations are frequent in 
tumors and in the germ line of patients with tumor predisposition or with neurological or cognitive 
disorders, which makes the PTEN gene and protein a major focus of interest in current biomedical 
research. After almost two decades of intense investigation on the 403-residue-long PTEN protein, 
a previously uncharacterized form of PTEN has been discovered that contains 173 amino-terminal 
extra amino acids, as a result of an alternate translation initiation site. To facilitate research in the 
field and to avoid ambiguities in the naming and identification of PTEN amino acids from 
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publications and databases, we propose here a unifying nomenclature and amino acid numbering 
for this longer form of PTEN.
Since the discovery in 1997 of a major tumor suppressor gene encoding a protein with 
tyrosine phosphatase activity—which was named PTEN (phosphatase and tensin homolog 
on chromosome ten), MMAC1, or TEP1 (1–3)—an outburst of publications have 
documented the relevance of PTEN (currently used protein name; official gene name PTEN) 
on tumor biology and human disease (4). The human PTEN gene is located at chromosome 
10q23, a locus frequently deleted in human cancers. In addition, PTEN is a common target 
of point mutations in tumors, including mutations at noncoding and nontranslated regions, as 
well as frameshift, missense, and nonsense mutations at coding regions. Patients with PHTS 
(PTEN hamartoma tumor syndrome), as well as a fraction of patients with ASD (autism 
spectrum disorders), carry germline PTEN mutations. In the case of PHTS patients, this 
confers high risk for several types of cancer, including (but not restricted to) breast and 
thyroid cancer (5–7). PTEN mutations at coding regions distribute all along the gene, and 
mutations are common in exons encoding the protein tyrosine phosphatase (PTP) catalytic 
domain, especially exon 5 (8). Although a large number of PTEN mutations found in tumors 
or in PHTS patients confer total loss of function to the protein, many mutations lead to 
partial loss of function or have a weak effect on PTEN phosphatase activity. Moreover, most 
of the germline PTEN mutations from ASD patients do not abrogate PTEN catalysis (9). 
This makes important not only identifying the PTEN mutation affecting the patient but also 
characterization of the functional properties of the corresponding mutated PTEN protein.
PTEN is one of relatively few genes in the human genome that encodes two proteins by 
noncanonical alternative initiation of translation (Fig. 1A). The shorter and more abundant 
PTEN protein contains 403 amino acids that distribute in two major domains: a catalytic 
PTP domain and a membrane-binding C2 domain (10). The recently identified and less 
abundant longer PTEN protein (named as PTEN-Long or PTENα, and here as PTEN-L) 
contains 173 additional amino-terminal intrinsically disordered amino acids, as a result of 
the usage of an alternative CUG translation initiation site upstream to the canonical AUG 
sequence used to produce the shorter 403-amino-acid form (11–13).
Different groups have proposed that PTEN-L can be secreted to enter other cells (11) and 
that it may form heterodimers with PTEN and regulate mitochondrial function (12). Adding 
to the functional complexity, PTEN also homodimerizes, which may be particularly 
important in tumors or patients coexpressing wild-type and mutated PTEN alleles (14). 
Mutations encoding residues in the specific region of PTEN-L occur in tumors or are 
reported as polymorphisms (15–19), and this region may control PTEN sub-cellular 
localization and tumor suppressor activity. For example, this region includes the 
internalization signal for uptake of PTEN-L into acceptor cells, a postulated physiologic 
mechanism for tumor suppression, which potentially could be used as a novel therapeutic 
approach to reconstitute PTEN activity in PTEN-deficient tumors (11, 20).
Abundant literature exists using the amino acid numbering from the short PTEN form, but 
this numbering does not fit with the amino acid numbering of PTEN-L. In addition, the 
numbering of the specific residues from PTEN-L (1 to 173) is already used to number 
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different residues in PTEN, which could generate confusion. For instance, residues 1 to 22 
from PTEN-L form part of a predicted secretion signal peptide, whereas residues 6 to 32 
from PTEN contain an overlapping PI(4,5)P2-binding motif, nuclear localization signal, and 
cytoplasmic localization signal (Fig. 1A) (21–23). Thus, we propose a unified numbering to 
designate amino acids in PTEN and PTEN-L, so as to avoid ambiguity in the identification 
of PTEN residues from mutated samples or in the precise naming of PTEN residues in 
experimental work (Fig. 1, B and C). Our proposal is as follows:
• PTEN-Long is named PTEN-L.
• The amino acid numbering of PTEN does not change.
• The amino acid numbering of PTEN-L is followed by -L, for example, Leu1-L, 
Glu2-L … in three-letter code or L1-L, E2-L … in single-letter code up to Val576-L 
or V576-L. Residues Leu1-L to Ser22-L form part of a predicted secretion signal 
and would not be present in a mature secreted form of PTEN-L protein.
• The equivalence between residues from PTEN and PTEN-L is calculated by adding 
173 to—or subtracting it from—the corresponding numbering. For instance, Cys124 
(C124) from PTEN is equivalent to Cys297-L (C297-L) from PTEN-L.
• Amino acid changes, either through site-directed mutagenesis or through naturally 
occurring mutations, are indicated as the residue and number without any extension 
for PTEN (for example, C124S), and with the -L extension for PTEN-L (for 
example, C297S-L) when the name of the protein is not immediately preceding the 
mutation name. Mutations commonly used in experimental work to abrogate the 
catalytic activity of PTEN are shown in Fig. 1B.
• Nucleotide numbering to desig-nate mutations at the PTEN-L–specific residues 
follows the Human Genome Variation Society (HGVS) recommendations (24). For 
instance, nucleotides −3 to −1 would encode Asp173-L; −6 to −4 would encode 
Pro172-L; up to −519 to −517, which would encode Leu1-L (Fig. 1C). Note that 
CUG −519 to −517 nucleotides in the HGVS-recommended numbering for human 
PTEN gene correspond to CUG 513 to 515 nucleotides in the human PTEN cDNA 
entry (NM_000314).
• Homodimers and heterodimers of PTEN proteins are designated with the 
appropriate extension as needed (Fig. 1D).
• Newly identified PTEN proteins with starting amino acids distinct from Met1 from 
PTEN or Leu1-L from PTEN-L could be named alphabetically as PTEN-M, PTEN-
N, and so on, or by using another appropriate capital letter, and the nomenclature 
for amino acids and amino acid changes would follow the rules as above for PTEN-
L.
• The same rules apply to other mammalian PTEN-L protein orthologs, especially 
those from animal models usually handled in biomedical research.
The possibility of numbering PTEN-L– specific residues with negative numbers starting at 
and going upstream from the canonical AUG initiation codon of PTEN (as recommended by 
the HGVS for mutations that introduce in proteins new translation initiation sites) is not 
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practical in the case of PTEN-L, because this form is produced from a natural, not mutation-
created, upstream alternative translation initiation codon (CUG) that generates a natural 
longer protein. The mutations affecting the PTEN-L–specific residues do not introduce new 
translation initiation sites, but rather change residues in PTEN-L.
We think that this unified nomenclature will facilitate to both researchers and clinicians the 
unambiguous identification of amino acids from PTEN and PTEN-L and aid in the 
description of any new forms that may be identified in the future.
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Fig. 1. A nomenclature for PTEN-L amino acid numbering
(A) Schematic of human PTEN and PTEN-L and the proposed numbering of amino acids. 
The domains common to PTEN and PTEN-L are indicated at the top, and the amino acids 
flanking the domains are indicated below each protein depiction. C124 (PTEN) or C297-L 
(PTEN-L) corresponds to the catalytic Cys. The N- and C-terminal tails from PTEN, and the 
PTEN-L–specific region (residues L1-L to D173-L) are intrinsically disordered regions. The 
black box at the N terminus of PTEN-L corresponds to a predicted secretion signal 
(predicted cleavage site at amino acid S22-L). PBM, PI(4,5)P2-binding motif; NLS, nuclear 
localization sequence; CLS, cytoplasmic localization sequence; PDZ-BM, PDZ-binding 
motif. Numbers at the bottom correspond to exon numbering. (B) Examples of nomenclature 
for commonly used PTEN mutations totally or partially defective for phosphatase activity 
(25–27). (C) Examples of nomenclature for identified PTEN mutations targeting PTEN-L–
specific amino acids. Loss of function has been experimentally observed for mutations 
A99T-L, H122Y-L, and R170G-L [(11); note that in reference (11) the amino acid 
numbering is one unit less]. *Reported as polymorphisms (15, 17). HNSCC, head and neck 
squamous cell carcinoma; LBCL, large B cell lymphoma; GBM, glioblastoma multiforme. 
(D) Examples of nomenclature for PTEN dimers. Examples are provided of different 
combinations of PTEN and PTEN-L wild-type and mutated homodimers and heterodimers. 
PTEN:PTEN homodimers (14) and PTEN:PTEN-L heterodimers (12) have been 
demonstrated experimentally. The possibility also exists of dimers containing two mutated 
proteins (with the same mutation or different mutations).
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